Background/Objectives: It is well established that combining a reduced calorie, low-fat diet with the lipase inhibitor orlistat results in significantly greater weight loss than placebo plus diet. This weight loss is accompanied by changes in adipose tissue (AT) distribution. As 60 mg orlistat is now available as an over-the-counter medication, the primary objective of this study was to determine whether 60 mg orlistat is effective as a weight loss option in a free-living community population with minimal professional input. Methods: AT and ectopic lipid content were measured using magnetic resonance imaging and 1 H MR spectroscopy, respectively, in 27 subjects following 3 months treatment with orlistat 60 mg and a reduced calorie, low-fat diet. Results: Significant reductions in intra-abdominal AT (À10.6%, P ¼ 0.023), subcutaneous (À11.7% Po0.0001) and pericardial fat (À9.8%, P ¼ 0.034) volumes and intrahepatocellular lipids (À43.3%, P ¼ 0.0003) were observed. These changes in body fat content and distribution were accompanied by improvements in plasma lipids and decreases in blood pressure and heart rate. Conclusion: These findings suggest that over-the-counter 60 mg orlistat, in combination with the type of advice a subject could expect to be given when obtaining 60 mg orlistat in a community setting, does indeed result in potentially clinically beneficial changes in body composition and risk factors for metabolic diseases.
Introduction
There is a paucity of prescription drugs available for longterm treatment of obesity. In Europe only Xenical (orlistat 120 mg) is currently licensed. In 2007, orlistat 60 mg (alli) was approved by the Food and Drug Administration as an over-the-counter weight loss medicine. The ability of orlistat 60 mg to significantly reduce body weight has been well demonstrated (Rössner et al., 2000; Brochu et al., 2003; Anderson et al., 2006; Anderson, 2007; Schwartz et al., 2008) . Furthermore previous randomised controlled trials have shown that orlistat 120 mg can result in beneficial changes in body composition (Kelley et al., 2004; Tiikkainen et al., 2004; Chanoine et al., 2005; Dixon et al., 2007) . There is now a need to understand whether orlistat 60 mg has a positive impact on weight loss and body composition in a free-living community.
Obesity is currently at epidemic proportions; in 2005, the World Health Organization stated that 1.6 billion adults were overweight worldwide, with 400 million classed as obese. Numbers are predicted to rise to 2.3 billion overweight and 700 million obese by 2015 (World Health Organisation, 2006) . These levels of obesity are associated with increasing morbidity and mortality connected with diseases, including type-2 diabetes, hypertension, dyslipidaemia and non-alcoholic fatty liver disease (Must et al., 1999) .
Risk of developing these chronic conditions is increased in individuals with abdominal obesity. Accumulation of excess intra-abdominal adipose tissue (IAAT) is a central feature of abdominal obesity. Indeed, elevated IAAT (commonly referred to as visceral fat) and intrahepatocellular lipid (IHCL) are markers of a dysmetabolic state, which increases the risk of type-2 diabetes and coronary artery disease (Després et al., 2008; Fabbrini et al., 2009) . The association between IAAT and accelerated atherosclerosis is independent of age, overall obesity or the amount of subcutaneous fat (Hamdy et al., 2006) .
It is well known that weight loss results in many health benefits (National Institutes of Health, 1998) . Reductions of 5-10% body weight improve many of the medical complications associated with excess weight (Goldstein, 1992) . Many of these benefits are associated with changes in body composition (Hauptman et al., 2000) .
Classically, anthropometric measures have been employed to assess body fat distribution. Availability of modern imaging methods for fat quantitation has become a focus of attention particularly in a clinical research setting. Studies using imaging techniques such as magnetic resonance imaging (MRI) have shown that reduction of AT from key sites known to have a specific pathological role, such as IAAT and IHCL, can result in significant improvements in risk of metabolic and cardiovascular disease (Thomas et al., 2000; Ross et al., 2004) .
Our aim was to undertake a pragmatic study to determine whether orlistat 60 mg when given with the minimal professional input, as would be encountered in a real community setting, would lead to beneficial changes in body composition, specifically reductions in IAAT and ectopic fat following 12 weeks of treatment in overweight and obese subjects. Both MRI and 1 H MR spectroscopy (MRS) imaging were used to measure these changes.
Materials and methods
Written informed consent was obtained from all participants. Ethical approval was obtained from The Joint South London and Maudsley and the Institute of Psychiatry National Health Service Research Ethics Committee (REC 08/H0807/88), London, UK.
Study population
Subjects were recruited by poster advertising in the local area and the Clinical Imaging Centre volunteer panel. This strategy proved effective among people working in a local prison and police force, partly explaining the bias towards male subjects.
Inclusion and exclusion criteria
Inclusion criteria was an age range of 18-60 years, body mass index (BMI) 25-34.9 kg/m 2 and a waist circumference (WC)
488 cm (female) or 4102 cm (male). Subjects were not eligible if they had recent history of weight loss or were taking prescription drugs that affected body weight or metabolism.
Study design
This was an open label, non-randomised, 12-week study with one screening and four study visits. As a non-prescription medication, the design was more similar to an 'actual use study', a trial that is usually conducted as part of a nonprescription submission in the United States to access appropriate usage (Brass, 2001) . In this type of study, there is not a control group. A full physical exam including electrocardiographs and vital signs, medical history review, urine drug screen, alcohol breath test, routine safety laboratory tests and pregnancy test in female subjects were obtained at the screening visit. Anthropometric measurements were collected, including WC, weight (kg) and height (m). Subjects were fasted for 8 h before screening and MR scans.
Diet. At the time the study was conducted, alli had not been approved in Europe. Subjects meeting the inclusion criteria were provided a 4-week supply of alli (60 mg orlistat), along with educational materials included in the US starter kit, and access to the US alli web site. The aim was to provide subjects with a similar experience to individuals purchasing alli in a real-life setting. At the baseline visit, subjects met a dietician who discussed the diet, highlighting the importance of reducing one's calories and sticking with the recommended fat intake. The dietician also reinforced the importance of keeping a dietary record as a method of understanding change in eating behaviour. This discussion was aimed to reflect a counselling session between a person buying alli over the counter for the first time and a pharmacist. Subjects were instructed to take the medication three times daily with each main meal and to take a multivitamin daily at least 2 h before or after taking 60 mg orlistat. Subjects were encouraged to exercise.
Dietary analysis
Dietary assessment was carried out at weeks 0 and 12 using a multipass 24 h recall (Bingham et al., 1997) . Dietary recall was analysed using Dietplan 6 (Forestfield Software Ltd, Horsham, UK) At baseline (study visit 1), MR images were obtained for measurement of abdominal subcutaneous AT (ASAT) and IAAT, as well as pericardial and intermuscular AT. Liver and soleus muscle lipid content was measured by MRS.
Study visits 2 and 3 were conducted at 4 and 8 weeks, respectively. During these visits, the subjects were queried about adverse events, had their weight and WC measured, returned any unused medication and received another 4-week supply of orlistat 60 mg. Any remaining capsules were counted to evaluate compliance with the study medication.
The final visit was at 12 weeks. Post-treatment MRI/MRS scans were conducted. Before the scans, the following assessments were completed: physical examination, body weight/height/waist measurement, fasting lipid blood sample, urine pregnancy test (if applicable) and routine safety laboratory tests.
MR imaging and spectroscopy MRI scanning was carried out on a 3T Siemens Tim Trio scanner (Siemens Healthcare, Erlangen, Germany).
MRI for abdominal and pericardial AT content. The torso was imaged using a 6-channel spine array and two 4-channel body array coils. Imaging data was generated using a threedimensional spoiled gradient echo sequence with partial Fourier acquisitions (Volume Interpolated Body Examination (VIBE); Rofsky et al., 1999) . The imaging volume consisted of four contiguous three-dimensional slabs, where each 48 Â 3.5 mm slice slab (1.76 Â 1.76 mm voxels) was acquired in a single 15 s end-expiration breath hold (repetition time ¼ 7 ms; echo times ¼ 2.45, 3.675 ms; flip angle ¼ 101; 450 mm field of view; 6/8 partial phase/slab Fourier; 75% slice resolution; 33% slice oversampling; GRAPPA factor 2; and noncardiac gated). The most inferior slab was positioned to begin at the pubic symphysis; the slabs covered 67.2 cm superior to this, which surpassed the top of the lungs. Two echoes per excitation were set to acquire fat and water signals in-phase and 1801 out of phase. These plus three-dimensional fieldmaps were used to decompose the signal into fat and water images.
MRI measurement of intermuscular AT. The position of the calf slice at baseline was marked at its thickest point. This was externally measured from the heel when seated with the knee at a 901 angle and was repeated at follow-up. Calf images were taken with a single VIBE volume (32 slices, 260 mm field of view), as described above, using a flexible coil wrapped around the calf.
MRI image analysis
Fat-only images in the abdomen were manually segmented into three compartments: IAAT, pericardial AT and ASAT. The abdominal area was defined using anatomical landmarks (top of femoral heads to the bottom of right lung; Thomas et al., 1998) . The volume of IAAT measured contains a mixture of visceral, peri-renal and retroperitoneal AT, as these cannot easily be differentiated on an MR image.
The fat-only image in the calf was segmented and intermuscular AT measured. All images were anonymised and blinded to time point, but not to subject, to facilitate matching anatomical landmarks, and analysed by Vardis (Vardis Group Inc., London, UK) using SliceOMatic (Tomovision, Montreal, Canada).
H MR spectroscopy
1 H MR spectra were obtained from the right lobe of the liver and the soleus muscle using a PRESS sequence with a 20 Â 20 Â 20 mm voxel (repetition time ¼ 1500 ms and echo time ¼ 30 ms). Spectra were analysed using the AMARES routine of the jMRUI software package (Naressi et al., 2001) . For the liver, the ratio fat/water was calculated using the areas under the water and CH 2 lipid resonances after correcting for T 1 and T 2 relaxation differences (Thomas et al., 2005) . For the soleus, the ratio intramyocellular lipid CH 2 /creatine was calculated after correcting for T 1 and T 2 (Rico-Sanz et al., 1999) .
Statistical analysis
The need for data transformation was explored for all end points, and log transformation was applied to MRI/MRS data to account for increased variability seen in larger values.
MRI/MRS data were analysed using analyses of covariance, and results presented as relative (percent) changes from baseline. Analyses of covariance were also used to analyse changes in lipids and vital signs. Changes in anthropometric end points (measured monthly) were analysed on the natural scale using mixed model repeated measures analyses.
All models accounted for effects of baseline, age and gender, and estimates of mean changes over time were presented with 95% confidence intervals and corresponding P-values. Associations between measurements were investigated by scatter plots and Pearson's correlation coefficients.
A number of data sets were not obtained or deemed to be of sufficient quality so as to be included in the overall data set, often relating to patient motion. Decisions were made before statistical analyses. Numbers of subjects included in final analyses are shown in Tables 2 and 3 .
Results
Twenty-seven subjects participated in this study; of these, 26 (7 female, 19 male) were exposed to orlistat. Twenty-four subjects completed the study. Most subjects were Caucasians (n ¼ 17), the others were Asians (n ¼ 5), Afro-Caribbeans (n ¼ 2) and of mixed race (n ¼ 2). The mean age of the participants was 39. 
Dietary analysis
Dietary analysis is shown in Table 1 . As expected for an obese population, there was an underestimation of total energy intake (Department of Health, 1991) . The estimated energy intake at baseline was 9944 ± 362 kJ verses an actual energy intake of 9279.2±334.4 kJ (Po0.01). By the end of the study, actual energy intake had reduced to 5158.7 ± 339.8 kJ (Po0.01), with significant decreases in protein, fat and carbohydrate intake. 
Change in body fat distribution
Following the 3-month intervention, there was a significant reduction in most AT depots measured (Table 2 and Figure 1 ). There was a significant reduction from baseline in IAAT (À11%, P ¼ 0.023), ASAT (À12%, Po0.0001), total abdominal fat (À12%, P ¼ 0.0001) and pericardial fat (À10%, P ¼ 0.034). Intermuscular AT did not show any significant reduction. We also found a highly significant reduction in IHCL (À43%, P ¼ 0.0003). There were no changes in soleusintramyocellular lipid.
Anthropometry changes
Significant reductions in body weight (À2.2%, Po0.0001), BMI (À2.2%, Po0.0001) and WC (À2.0%, Po0.0001) were detected by the first follow-up visit at 1 month (Figure 2 ). Further reductions were observed at both 2-and 3-month time points. Overall there were significant reductions from baseline in BMI (À5.6%, Po0.0001), WC (À4.3%, Po0.0001) and weight (À5.6%, Po0.0001) following the intervention.
Biochemical and physiological changes
Significant reductions from baseline were found for total cholesterol (À10.5%, Po0.0001), low-density lipoprotein (À13.4%, P ¼ 0.0002) and high-density lipoprotein cholesterol (À5.2%, Po0.0178) over the 3-month treatment, as shown in Table 3 . Changes in triglyceride levels were not significant (À5.4%, P ¼ 0.3). Improvements in liver function were observed, with a significant reduction in alanine transaminase (À19.3%, P ¼ 0.0078). Reductions in aspartate aminotransferase were observed but did not reach significance (À9.0%, P ¼ 0.056). There were also significant reductions in heart rate (À8.6%, P ¼ 0.0027) and both systolic (À4.8%, P ¼ 0.0082) and diastolic (À6.3%, P ¼ 0.0003) blood pressure.
Correlations between changes in end points at 3 months Changes in IAAT were significantly correlated with changes in weight (r ¼ 0.68, P ¼ 0.0009), but not with changes in WC (r ¼ 0.22, P ¼ 0.3583). Changes in ASAT were significantly correlated with both weight (r ¼ 0.92, Po0.0001) and WC (r ¼ 0.59, P ¼ 0.0094). Changes in IHCL were significantly correlated with changes in weight (r ¼ 0.68, P ¼ 0.0005) and all AT depots (IAAT: r ¼ 0.70, P ¼ 0.0008; ASAT: r ¼ 0.72, P ¼ 0.0008; and pericardial AT: r ¼ 0.57, P ¼ 0.0094).
Changes in pericardial AT were most strongly correlated with changes in IAAT (r ¼ 0.88, Po0.0001). Interestingly, although changes in pericardial AT were correlated with changes in other AT depots and body weight (r ¼ 0.52, P ¼ 0.015), there was no relationship with changes in WC (r ¼ À0.04, P ¼ 0.88) or total cholesterol (r ¼ 0.12, P ¼ 0.61).
A significant relationship was observed between reduction in body weight and changes in blood pressure (systolic: r ¼ 0.40, P ¼ 0.050 and diastolic: r ¼ 0.47, P ¼ 0.020) and heart rate (r ¼ 0.51, P ¼ 0.01). There was no relationship between changes in IAAT and these parameters. Finally, there was a significant correlation between reductions of body weight and low-density lipoprotein cholesterol (r ¼ 0.55, P ¼ 0.0049) and between decreases in IAAT and high-density lipoprotein cholesterol (r ¼ 0.61, P ¼ 0.0042). 
Drop-outs and adverse effects
Most subjects completed the intervention, with only two subjects withdrawing from the study. Several subjects reported adverse effects during the intervention, which were mild and most commonly gastrointestinal related (n ¼ 10, 38%). Consistent with previous orlistat studies, diarrhoea was reported by some subjects (n ¼ 7, 27%).
Discussion
Our results show that even with minimal professional input, which would be typical when buying orlistat in an over-thecounter setting, overweight and obese subjects receiving orlistat 60 mg for 12 weeks showed significant reductions in IAAT and ASAT. We also found significant reductions in pericardial fat volumes and intrahepatic lipids following treatment with orlistat 60 mg. Dietary assessment demonstrated a significant decrease in energy intake, with a fall in all macronutrients.
In addition to reductions in body fat depots, following a 12-week intervention, we found with orlistat 60 mg a mean 5.6% decrease in weight, a 4.3% reduction in WC and a 1.7 unit change in BMI. Changes in weight and WC were accompanied by improvements in blood lipids, liver function tests and blood pressure.
These findings are in accordance with previous research demonstrating the efficacy of orlistat 60 mg in reducing body weight and weight-related comorbidities (Anderson et al., 2006; Anderson, 2007) . The magnitude of the effects is similar to those reported previously by others. Schwartz et al. (2008) in an over-the-counter minimal intervention study of orlistat (60 mg) plus written dietary advice on diet and behaviour change reported that subjects lost 4.6 ± 0.7 kg. Tiikkainen et al. reported that orlistat (120 mg) has a beneficial effect of AT distribution. In their study of 47 women, they showed reductions in both IAAT and SAT in both orlistat and placebo groups, but found that the ratio of IAAT to total AT only decreased in the orlistat group, suggesting that reduced fat absorption has an additional benefit over weight loss per se (Tiikkainen et al., 2004) . Kelley et al. (2004) have previously shown reduced IAAT and improved insulin sensitivity in type 2 diabetic subjects following orlistat (120 mg) for 6 months with diet and exercise. Interestingly, changes in weight loss and IAAT were not significantly different between orlistat and placebo. Greater reductions in metabolic markers, including fasting insulin and plasma free fatty acids, and greater improvements in insulin insensitivity were attributed to orlistat. In the present study, we demonstrated improvements in body composition and biomarkers such as low-density lipoprotein cholesterol with a lower-dose orlistat, despite a shorter study duration, in non-diabetic subjects with minimal professional input. In the Kelley Study, subjects met a nutritionist weekly, whereas in the current study, participants met a dietician at the beginning and end of the study. Orlistat 120 mg in combination with diet has been shown to reduce liver fat in patients with type 2 diabetes (Kelley et al., 2004) and non-alcoholic steatohepatitis, and reduce inflammation and fibrosis in non-alcoholic steatohepatitis (Hussein et al., 2007) . In the present study, we found a 43% reduction in IHCL, with modest weight loss (5.6% over 3 month's treatment). Considering the key role of IHCL in the development of insulin resistance (Fabbrini et al., 2009 ), this finding is important and needs further exploration.
We observed a significant reduction in pericardial fat despite modest weight loss. Previous studies have reported loss of pericardial fat following greater weight loss over a 6-month period (Iacobellis et al., 2008) . This is the first time that changes in pericardial AT have been demonstrated in patients using orlistat. Reductions in pericardial AT were significantly related to changes in body weight, IAAT and IHCL, although there was no relationship with changes in WC and biochemical markers.
Previous studies suggest that some weight loss treatments may preferentially reduce IAAT compared with subcutaneous deposits (Thomas et al., 2000; Hamdy et al., 2006; Chaston and Dixon, 2008) . However, the current study found that orlistat combined with diet reduced AT to a similar extent in both internal (IAAT and pericardial) and subcutaneous depots.
We found no significant correlation between changes in IAAT and WC despite both reducing during the intervention. WC is often reported as an indirect marker of IAAT content. However, it has been suggested that WC is no better a predictor of IAAT than BMI (Oka et al., 2009) . Furthermore, it has recently been shown that WC acts predominantly as an index of ASAT (Bosy-Westphal et al., 2010) , which may in part explain the findings in the current study.
No significant changes were observed in muscular AT, located as either intramyocellular lipid or intermuscular AT. It is possible that changes in these depots may be secondary to reductions in abdominal AT depots. This would be in keeping with our previous observations of reductions in IAAT, ASAT and IHCL following life-style-induced weight loss. Changes in soleus-intramyocellular lipid appear to follow only in response to greater weight loss (Thomas et al., 2006) . This study used novel technologies to provide a comprehensive assessment of the effects of orlistat 60 mg on body composition. As the effects of orlistat (120 mg) on weight loss and body composition are well established, we did not employ a placebo or diet-only group. The precise contribution of orlistat 60 mg per se cannot therefore be determined with certainty; however, the weight loss results were consistent with what has been observed in other trials of orlistat 60 mg (Anderson et al., 2006; Anderson, 2007) . Previous studies have shown that slightly more weight is lost over 12 months with orlistat 120 mg (Rössner et al., 2000; Brochu et al., 2003) ; however, in the current study, 3 months of 60 mg orlistat with minimal professional input produced significant weight loss, resulting in a more favourable body fat distribution, specifically reduced IAAT, IHCL and pericardial fat, accompanied by potential health benefits improved plasma lipid profiles, and reduced blood pressure.
Conclusions
These findings suggest that over-the-counter 60 mg orlistat, in combination with the type of advice a subject could expect to be given when obtaining 60 mg orlistat in a community setting, does indeed result in potentially clinically beneficial changes in body composition and risk factors for metabolic diseases.
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